Podcast Pearls: Evolving Treatment Landscape With Regorafenib and TAS-102 in Metastatic Colorectal Cancer

Download this slideset for key insights from a podcast featuring an expert discussion of current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC.
Nilofer S. Azad, MD
Kanwal Raghav, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 273 KB
Released: April 6, 2022

Acknowledgements

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Downloadable slideset with highlights from key gastrointestinal cancers as presented at 2022 ESMO World Congress on Gastrointestinal Cancer, from Clinical Care Options (CCO)

Released: August 16, 2022

Expert commentary on potential clinical implications of findings from the MOUNTAINEER trial with tucatinib and trastuzumab in HER2 positive metastatic colorectal cancer, from Clinical Care Options (CCO)

John Strickler, MD Released: August 10, 2022

Nina Beri, MD reviews ongoing clinical trials in targeted therapies for patients with cholangiocarcinoma presented at ASCO 2022, from Clinical Care Options (CCO)

person default Nina Beri, MD Released: August 3, 2022

Downloadable slideset on therapies for previously treated advanced HER2-negative gastric/GEJ cancers, from Clinical Care Options (CCO)

Samuel Klempner, MD Released: July 21, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings